James D. Clark - Concepedia

Author

James D. Clark

Also Known As

Clark, James D., J Clark, J D Clark, J David Clark, J. Clark, J. D. Clark, J. David Clark, J.D. Clark, J. David Clark, James Clark

104

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Inflammation Research Foundation Stanford University VA Palo Alto Health Care System Harvard University

About

James D. Clark is an author at Pfizer (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	26	4.3K
2	Natural Sciences	9	9	2.8K
3	Social Sciences	3	3	154
4	Health Sciences	1	1	126
5	Behavioral Sciences	1	1	44

James D. Clark

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP James D. Clark, Lih‐Ling Lin, Ronald Kriz, Cell Signal TransductionMolecular PhysiologyBiochemistryNatural SciencesCa2+-dependent Translocation Domain	1991	1.7K
Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937. James D. Clark, N Milona, John L. Knopf Proceedings of the National Academy of Sciences U937 CellsSignal TransductionBiochemistryCell SignalingMedicine	1990	429
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Jennifer Hodge, Thomas T. Kawabata, Sriram Krishnaswami, PubMed ImmunologyBiological TherapyInflammationRheumatoid DisorderReceptor Tyrosine Kinase	2016	371
Crystal Structure of Human Cytosolic Phospholipase A2 Reveals a Novel Topology and Catalytic Mechanism Andréa Dessen, Jin Tang, Mark Stahl, Cell Crystal StructureProteinlipid InteractionProtein FunctionSignal TransductionNovel Topology	1999	365
Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca(2+)-dependent lipid-binding domain and a Ca(2+)-independent catalytic domain. Eric A. Nalefski, Lisa A. Sultzman, David Martin, Journal of Biological Chemistry	1994	352
Parsing the Interferon Transcriptional Network and Its Disease Associations Sara Mostafavi, Hideyuki Yoshida, Devapregasan Moodley, Cell	2016	336
Prevalence of sexual dimorphism in mammalian phenotypic traits Natasha A. Karp, Jeremy Mason, Arthur L. Beaudet, Nature Communications	2017	267
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition Jean‐Baptiste Telliez, Martin E. Dowty, Lu Wang, ACS Chemical Biology Jak1 InhibitionImmunologyImmune RegulationInnate ImmunityInflammatory Arthritis	2016	187
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( <i>S</i> )-2,2-Difluorocyclopropyl)((1 <i>R</i> ,5 <i>S</i> )-3-(2-((1-methyl-1 <i>H</i> -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841) Andrew Fensome, Catherine M. Ambler, Eric P. Arnold, Journal of Medicinal Chemistry	2018	165
Identification of <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases Michael L. Vazquez, Neelu Kaila, Joseph W. Strohbach, Journal of Medicinal Chemistry ImmunodeficienciesJanus KinasesImmunologyPharmacotherapyImmunotherapy	2018	160

Page 1